Remove 2003 Remove Licensing Remove Marketing
article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

Since licensed by Ridgeback all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck. Ridgeback markets EbangaTM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19. About Ridgeback Biotherapeutics.

Trials 69
article thumbnail

BioArctic receives European patent for new antibodies targeting Alzheimer’s disease

The Pharma Data

The company was founded in 2003 based on innovative research from Uppsala University , Sweden. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.

Disease 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bridging science and technology: a biotech CEO’s perspective

Drug Target Review

As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge.

Science 52
article thumbnail

PREA and Fixed-Dose Combinations: When Things Get Complicated

The Premier Consulting Blog

The Pediatric Research Equity Act (PREA) was signed into law in 2003 to increase pediatric use information in product labeling and close knowledge gaps regarding the safety, efficacy, and appropriate dosing of drugs to treat children.

article thumbnail

Decades Later, Congress Continues Debating the Preserve Access to Affordable Generics (and Biosimilars) Act; But will the Recent Jarkesy SCOTUS Decision Finally Put an End to the Insanity?

FDA Law Blog: Biosimilars

3582 went nowhere; and many additional unsuccessful attempts to get a similar bill passed followed over the years. But like cockroaches, some pieces of legislation are resilient and never seem to die. 3) A covenant not to sue on any claim that the ANDA product or biosimilar biological product infringes a United States patent.

article thumbnail

Blocked Transmission

Codon

It was March 2003, and an unfortunate 33-year-old, known only as patient YY, was suffering from intense diarrhea. A company called LuminOre will soon bring copper-coated air ducts to the market. Tom Ough writes about how UVC light, metals, and surface coatings can help fend off pathogens for Issue 01. Read it on our website here.

Virus 73
article thumbnail

Article FDA Thank You FDA unveils long-awaited Patient Medication Information proposed rule

Agency IQ

Given the number of approved drugs and biologics on the market that are dispensed on an outpatient basis – and their generic and biosimilar equivalents – the additional workload on FDA’s labeling review staff could be considerable. However, only licensed blood establishments would be required to submit PMI to FDA for approval.”

FDA 40